DE10334188B4 - Verwendung von Rotigotin zur Behandlung von Depressionen - Google Patents

Verwendung von Rotigotin zur Behandlung von Depressionen Download PDF

Info

Publication number
DE10334188B4
DE10334188B4 DE10334188A DE10334188A DE10334188B4 DE 10334188 B4 DE10334188 B4 DE 10334188B4 DE 10334188 A DE10334188 A DE 10334188A DE 10334188 A DE10334188 A DE 10334188A DE 10334188 B4 DE10334188 B4 DE 10334188B4
Authority
DE
Germany
Prior art keywords
rotigotine
depression
use according
acid
depressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE10334188A
Other languages
German (de)
English (en)
Other versions
DE10334188A1 (de
Inventor
Dieter Scheller
Alexander Breidenbach
Norma Selve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34088862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10334188(B4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Priority to DE10334188A priority Critical patent/DE10334188B4/de
Priority to AT04741204T priority patent/ATE478660T1/de
Priority to CNB2004800217910A priority patent/CN100430050C/zh
Priority to PCT/EP2004/008168 priority patent/WO2005009424A1/de
Priority to DE502004011581T priority patent/DE502004011581D1/de
Priority to UAA200600333A priority patent/UA83493C2/uk
Priority to DK04741204.4T priority patent/DK1648432T3/da
Priority to ES04741204T priority patent/ES2351190T3/es
Priority to AU2004258697A priority patent/AU2004258697B2/en
Priority to EA200600222A priority patent/EA009784B1/ru
Priority to US10/565,699 priority patent/US8754119B2/en
Priority to KR1020067001785A priority patent/KR101140510B1/ko
Priority to EP04741204A priority patent/EP1648432B1/de
Priority to NZ545063A priority patent/NZ545063A/en
Priority to JP2006521476A priority patent/JP5001651B2/ja
Priority to CA2532859A priority patent/CA2532859C/en
Priority to BRPI0413000-6A priority patent/BRPI0413000A/pt
Priority to HK06111851.9A priority patent/HK1091131B/xx
Priority to MXPA06000782A priority patent/MXPA06000782A/es
Priority to PL04741204T priority patent/PL1648432T3/pl
Publication of DE10334188A1 publication Critical patent/DE10334188A1/de
Priority to IL173028A priority patent/IL173028A/en
Priority to IS8229A priority patent/IS8229A/is
Priority to NO20060846A priority patent/NO335666B1/no
Priority to ZA200600341A priority patent/ZA200600341B/xx
Publication of DE10334188B4 publication Critical patent/DE10334188B4/de
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DE10334188A 2003-07-26 2003-07-26 Verwendung von Rotigotin zur Behandlung von Depressionen Expired - Fee Related DE10334188B4 (de)

Priority Applications (24)

Application Number Priority Date Filing Date Title
DE10334188A DE10334188B4 (de) 2003-07-26 2003-07-26 Verwendung von Rotigotin zur Behandlung von Depressionen
EP04741204A EP1648432B1 (de) 2003-07-26 2004-07-22 Verwendung von rotigotin zur behandlung von depressionen
JP2006521476A JP5001651B2 (ja) 2003-07-26 2004-07-22 うつ病の治療のためのロチゴチンの使用
PCT/EP2004/008168 WO2005009424A1 (de) 2003-07-26 2004-07-22 Verwendung von rotigotin zur behandlung von depressionen
DE502004011581T DE502004011581D1 (de) 2003-07-26 2004-07-22 Verwendung von rotigotin zur behandlung von depressionen
UAA200600333A UA83493C2 (uk) 2003-07-26 2004-07-22 Застосування ротиготину для лікування депресії
DK04741204.4T DK1648432T3 (da) 2003-07-26 2004-07-22 Anvendelse af rotigotin til behandling af depressioner
ES04741204T ES2351190T3 (es) 2003-07-26 2004-07-22 Utilización de rotigotina para el tratamiento de depresiones.
AU2004258697A AU2004258697B2 (en) 2003-07-26 2004-07-22 Use of rotigotine for the treatment of depression
EA200600222A EA009784B1 (ru) 2003-07-26 2004-07-22 Применение ротиготина для лечения депрессии
US10/565,699 US8754119B2 (en) 2003-07-26 2004-07-22 Use of rotigotine for the treatment of depression
KR1020067001785A KR101140510B1 (ko) 2003-07-26 2004-07-22 우울증 치료용 로티고틴의 용도
AT04741204T ATE478660T1 (de) 2003-07-26 2004-07-22 Verwendung von rotigotin zur behandlung von depressionen
NZ545063A NZ545063A (en) 2003-07-26 2004-07-22 Use of (-)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol for the treatment of depression
CNB2004800217910A CN100430050C (zh) 2003-07-26 2004-07-22 罗替戈汀用于生产治疗抑郁症的药物的用途
CA2532859A CA2532859C (en) 2003-07-26 2004-07-22 Use of rotigotine for the treatment of depression
BRPI0413000-6A BRPI0413000A (pt) 2003-07-26 2004-07-22 uso de rotigotina para o tratamento de depressão
HK06111851.9A HK1091131B (en) 2003-07-26 2004-07-22 Use of rotigotine for the treatment of depression
MXPA06000782A MXPA06000782A (es) 2003-07-26 2004-07-22 Uso de rotigotina para el tratamiento de la depresion.
PL04741204T PL1648432T3 (pl) 2003-07-26 2004-07-22 Zastosowanie rotygotyny do leczenia depresji
IL173028A IL173028A (en) 2003-07-26 2006-01-09 Use of rotigotine for the preparation of a medicament for the treatment of depression
IS8229A IS8229A (is) 2003-07-26 2006-01-12 Notkun á rótigótíni við meðferð á þugnlyndi
NO20060846A NO335666B1 (no) 2003-07-26 2006-02-21 Anvendelse av rotigotin til behandling av depresjon
ZA200600341A ZA200600341B (en) 2003-07-26 2006-09-01 Use of rotigotine for the treatment of depression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10334188A DE10334188B4 (de) 2003-07-26 2003-07-26 Verwendung von Rotigotin zur Behandlung von Depressionen

Publications (2)

Publication Number Publication Date
DE10334188A1 DE10334188A1 (de) 2005-03-03
DE10334188B4 true DE10334188B4 (de) 2007-07-05

Family

ID=34088862

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10334188A Expired - Fee Related DE10334188B4 (de) 2003-07-26 2003-07-26 Verwendung von Rotigotin zur Behandlung von Depressionen
DE502004011581T Expired - Lifetime DE502004011581D1 (de) 2003-07-26 2004-07-22 Verwendung von rotigotin zur behandlung von depressionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE502004011581T Expired - Lifetime DE502004011581D1 (de) 2003-07-26 2004-07-22 Verwendung von rotigotin zur behandlung von depressionen

Country Status (22)

Country Link
US (1) US8754119B2 (enExample)
EP (1) EP1648432B1 (enExample)
JP (1) JP5001651B2 (enExample)
KR (1) KR101140510B1 (enExample)
CN (1) CN100430050C (enExample)
AT (1) ATE478660T1 (enExample)
AU (1) AU2004258697B2 (enExample)
BR (1) BRPI0413000A (enExample)
CA (1) CA2532859C (enExample)
DE (2) DE10334188B4 (enExample)
DK (1) DK1648432T3 (enExample)
EA (1) EA009784B1 (enExample)
ES (1) ES2351190T3 (enExample)
IL (1) IL173028A (enExample)
IS (1) IS8229A (enExample)
MX (1) MXPA06000782A (enExample)
NO (1) NO335666B1 (enExample)
NZ (1) NZ545063A (enExample)
PL (1) PL1648432T3 (enExample)
UA (1) UA83493C2 (enExample)
WO (1) WO2005009424A1 (enExample)
ZA (1) ZA200600341B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
ES2239196T3 (es) 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
AU2005287743B2 (en) * 2004-09-21 2011-09-29 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
PL2215072T3 (pl) 2007-11-28 2015-12-31 Ucb Pharma Gmbh Polimorficzna postać rotygotyny
CA2748235A1 (en) * 2008-12-24 2010-07-01 Astrazeneca Ab Ethanamine compounds and their use for treating depression
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EA025584B1 (ru) 2009-12-22 2017-01-30 ЮСиБи ФАРМА ГМБХ Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина
EP2531486B1 (en) 2010-02-05 2017-06-21 UCB Biopharma SPRL Novel process for the preparation of nitrogen substituted aminotetralins derivatives
WO2011161255A2 (en) 2010-06-25 2011-12-29 Ucb Pharma Gmbh Novel process for the preparation of nitrogen substituted aminotetralins derivatives
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
WO2013075822A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system (tts) with rotigotine
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
JP6599899B2 (ja) 2014-05-20 2019-10-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 界面介在物を含む経皮送達システム
CA2948220C (en) 2014-05-20 2023-06-20 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
SI3261645T1 (sl) 2015-02-27 2021-08-31 Dechra Limited Stimulacija apetita, uravnavanje izgube mase in zdravljenje anoreksije pri psih in mačkah
DK3491014T5 (da) * 2016-07-28 2024-09-02 Regeneron Pharma Allel-specifik primer eller sonde, som er hybridiseret til et nucleinsyremolekyle, som koder for en GPR156 variant
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
ES2966170T3 (es) 2020-01-24 2024-04-18 Luye Pharma Switzerland Ag Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US326830A (en) * 1885-09-22 Agitator for washing-machines
US4320148A (en) * 1980-11-24 1982-03-16 Smithkline Corporation 2-Aminotetralin compounds, pharmaceutical compositions and method of producing central alpha1 agonist activity
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US5298513A (en) * 1986-12-10 1994-03-29 Bayer Aktiengesellschaft Substituted basic 2-aminotetralin in pharmaceuticals
US5545755A (en) * 1989-05-31 1996-08-13 The Upjohn Company Therapeutically useful 2-aminotetralin derivatives

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3062971D1 (en) * 1979-09-14 1983-06-09 Sandoz Ag Derivatives of tetraline, their preparation and medicaments containing these compounds
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
CH649300A5 (de) * 1981-08-07 1985-05-15 Sandoz Ag Ergopeptinderivate, ihre herstellung und verwendung.
US4722933A (en) * 1985-12-20 1988-02-02 Nelson Research & Development Co. Substituted 2-aminotetralins
US5177112A (en) * 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4501890A (en) * 1983-09-26 1985-02-26 Eli Lilly And Company Trans-(±)-2,4,6-substituted-5,5a,6,7,8,9,9a,10-octahydro-pyrimido[4,5-g]quinolines
US4996226A (en) * 1984-08-13 1991-02-26 Whitby Research, Inc. Method and compositions for treatment of parkinsonism syndrome in mammels
US4885308A (en) * 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals
DE3535929A1 (de) * 1985-10-04 1987-04-09 Schering Ag 1,2-disubstituierte ergolinderivate
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
FR2613365B1 (fr) * 1987-04-01 1989-07-28 Adir Nouveaux derives de l'amino tetrahydro-5, 6, 7, 8 naphto (2, 3b) furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
CA1331191C (en) * 1988-03-25 1994-08-02 Bengt Ronny Andersson Therapeutically useful tetralin derivatives
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
CA2051399C (en) * 1989-05-31 2003-12-30 Chiu-Hong Lin Therapeutically useful 2-aminotetralin derivatives
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
DE69231854T2 (de) * 1991-04-17 2001-10-04 Pharmacia & Upjohn Co., Kalamazoo Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
GB9202915D0 (en) 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5663167A (en) * 1992-12-09 1997-09-02 The United States Of America As Represented By The Department Of Health And Human Services Antipsychotic composition and method of treatment
EP0710106A4 (en) 1993-03-17 1999-07-21 Pietr Hitzig METHOD FOR TREATING ADDICTIVE BEHAVIOR
SE9301732D0 (sv) 1993-05-18 1993-05-18 Haakan Wilhelm Wikstroem New centrally acting 5-,6-,7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins
DE4325855A1 (de) 1993-08-02 1995-02-09 Boehringer Ingelheim Kg Neue Benzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
TW280819B (enExample) * 1993-11-17 1996-07-11 Sumitomo Pharma
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
US5658955A (en) * 1994-11-01 1997-08-19 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of immune disorders
IT1276522B1 (it) * 1995-04-07 1997-10-31 Elena Benincasa Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
AU7238896A (en) 1995-09-14 1997-04-01 Cygnus, Inc. High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6010877A (en) * 1997-01-10 2000-01-04 Smithkline Beecham Corporation cDNA clone HE8CS41 that encodes a novel 7-transmembrane receptor
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
US6221627B1 (en) * 1997-02-24 2001-04-24 Smithkline Beecham Corporation cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor
IT1292155B1 (it) * 1997-06-13 1999-01-25 Zambon Spa Derivati naftotiazolonici attivi sul recettore dopaminergico d 3
NZ504108A (en) 1997-09-26 2002-06-28 Noven Pharma Bioadhesive compositions comprising a polyvinylpyrrolidone polymer and methods for topical administration of active agents
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
AU5325000A (en) * 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
HK1052514A1 (zh) * 1999-11-23 2003-09-19 阿德里斯制药公司 制备氮取代的氨基1，2，3，4-四氢化萘的改进方法
US6350773B1 (en) * 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
CA2425187A1 (en) * 2000-10-09 2002-04-18 Kay Double Detection of neurodegenerative disorders
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US20020177626A1 (en) * 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
ATE246919T1 (de) 2001-05-08 2003-08-15 Sanol Arznei Schwarz Gmbh Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
EP1344522A1 (en) * 2001-05-08 2003-09-17 Schwarz Pharma Ag Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
FR2829028B1 (fr) * 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
US20030225002A1 (en) * 2002-02-26 2003-12-04 Livingstone Ian R. Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
EP1494664A2 (en) * 2002-04-18 2005-01-12 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US20060216336A1 (en) * 2002-05-07 2006-09-28 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
EP1578719A4 (en) * 2002-10-25 2006-07-05 Collegium Pharmaceutical Inc P-HYDROXY-MILNACIPRAN STEREOISOMERS AND METHODS OF USING THE SAME
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
EP1708706A1 (en) * 2004-01-22 2006-10-11 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1778685B1 (de) 2004-08-02 2008-03-26 Schwarz Pharma Ag Carboxamide des indolizins und seiner aza- und diazaderivate
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
PL2215072T3 (pl) * 2007-11-28 2015-12-31 Ucb Pharma Gmbh Polimorficzna postać rotygotyny
EP2281559A1 (en) * 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EA025584B1 (ru) * 2009-12-22 2017-01-30 ЮСиБи ФАРМА ГМБХ Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US326830A (en) * 1885-09-22 Agitator for washing-machines
US4320148A (en) * 1980-11-24 1982-03-16 Smithkline Corporation 2-Aminotetralin compounds, pharmaceutical compositions and method of producing central alpha1 agonist activity
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US5298513A (en) * 1986-12-10 1994-03-29 Bayer Aktiengesellschaft Substituted basic 2-aminotetralin in pharmaceuticals
US5545755A (en) * 1989-05-31 1996-08-13 The Upjohn Company Therapeutically useful 2-aminotetralin derivatives

Also Published As

Publication number Publication date
US20070093546A1 (en) 2007-04-26
PL1648432T3 (pl) 2011-02-28
CN1829502A (zh) 2006-09-06
US8754119B2 (en) 2014-06-17
NO335666B1 (no) 2015-01-19
KR101140510B1 (ko) 2012-04-30
EA200600222A1 (ru) 2006-08-25
ATE478660T1 (de) 2010-09-15
HK1091131A1 (zh) 2007-01-12
EP1648432A1 (de) 2006-04-26
KR20060040723A (ko) 2006-05-10
IS8229A (is) 2006-01-12
CN100430050C (zh) 2008-11-05
BRPI0413000A (pt) 2006-09-26
DE502004011581D1 (de) 2010-10-07
ES2351190T3 (es) 2011-02-01
IL173028A0 (en) 2006-06-11
NO20060846L (no) 2006-02-21
ZA200600341B (en) 2006-11-29
NZ545063A (en) 2009-10-30
DE10334188A1 (de) 2005-03-03
JP5001651B2 (ja) 2012-08-15
CA2532859A1 (en) 2005-02-03
IL173028A (en) 2010-05-17
MXPA06000782A (es) 2006-04-18
EP1648432B1 (de) 2010-08-25
CA2532859C (en) 2013-12-03
UA83493C2 (uk) 2008-07-25
EA009784B1 (ru) 2008-04-28
AU2004258697A1 (en) 2005-02-03
DK1648432T3 (da) 2010-12-13
WO2005009424A1 (de) 2005-02-03
AU2004258697B2 (en) 2009-10-01
JP2007500154A (ja) 2007-01-11

Similar Documents

Publication Publication Date Title
DE10334188B4 (de) Verwendung von Rotigotin zur Behandlung von Depressionen
EP1648433B1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
DE102004014841B4 (de) Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1696904B1 (de) Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes
DE69921157T2 (de) Verwendungsmethoden und zusammenstellungen die einen dopaminewiederaufnahmeinhibitor enthalten
DE10361258A1 (de) Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE60120109T2 (de) Verfahren zur herstellung von optisch reinem (r)- und (s)- didesmethylsibutramin
DE69607904T2 (de) Potenzierung von Serotonin-Wirkstoffresponz
Faron-Górecka et al. Effects of tramadol on α2-adrenergic receptors in the rat brain
EP1461042B1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
JPS5824520A (ja) 精神病治療薬
Maan Comparison of Methamphetamine and MDMA Extended Access Self-administration: Acquisition, Maintenance, and Response Patterns
Bo et al. Antagonism of eegraphic and behavioural effects of methamphetamine by selective receptor blockers (SCH 23390 and raclopride) in the rabbit
HK1091131B (en) Use of rotigotine for the treatment of depression

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UCB PHARMA GMBH, 40789 MONHEIM, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee